Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. Show more

Location: 855 Oak Grove Avenue, Menlo Park, CA, 94025, United States | Website: https://orukatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.461B

52 Wk Range

$5.49 - $32.28

Previous Close

$30.21

Open

$30.07

Volume

697,844

Day Range

$29.38 - $31.08

Enterprise Value

1.117B

Cash

349.2M

Avg Qtr Burn

-22.42M

Insider Ownership

2.95%

Institutional Own.

95.20%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.